Minerva Neurosciences, Inc (NERV) News
Filter NERV News Items
NERV News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest NERV News From Around the Web
Below are the latest news stories about Minerva Neurosciences Inc that investors may wish to consider to help them evaluate NERV as an investment opportunity.
Insider Selling: Minerva Neurosciences, Inc. (NASDAQ:NERV) Director Sells 55,635 Shares of StockMinerva Neurosciences, Inc. (NASDAQ:NERV) Director David Kupfer sold 55,635 shares of the stock in a transaction dated Wednesday, December 1st. The shares were sold at an average price of $0.88, for a total transaction of $48,958.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through [] |
Minerva Neurosciences (NASDAQ:NERV) Upgraded to Buy at Zacks Investment ResearchZacks Investment Research upgraded shares of Minerva Neurosciences (NASDAQ:NERV) from a hold rating to a buy rating in a report released on Friday morning, Zacks.com reports. They currently have $1.00 target price on the biopharmaceutical companys stock. According to Zacks, Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and [] |
Minerva Neurosciences (NASDAQ:NERV) Stock Rating Upgraded by Zacks Investment ResearchMinerva Neurosciences (NASDAQ:NERV) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a note issued to investors on Friday, Zacks.com reports. The brokerage currently has a $1.00 target price on the biopharmaceutical companys stock. Zacks Investment Researchs price objective indicates a potential upside of 7.99% from the companys current [] |
Minerva Neurosciences (NASDAQ:NERV) Downgraded to Hold at Zacks Investment ResearchZacks Investment Research cut shares of Minerva Neurosciences (NASDAQ:NERV) from a buy rating to a hold rating in a research report report published on Wednesday, Zacks.com reports. According to Zacks, Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central [] |
Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Zacks Investment Research Downgrades Minerva Neurosciences (NASDAQ:NERV) to HoldZacks Investment Research cut shares of Minerva Neurosciences (NASDAQ:NERV) from a buy rating to a hold rating in a research report sent to investors on Tuesday, Zacks.com reports. According to Zacks, Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat [] The post Zacks Investment Research Downgrades Minerva Neurosciences (NASDAQ:NERV) to Hold appeared first on ETF Daily News . |
Minerva Neurosciences (NASDAQ:NERV) Raised to “Buy” at Zacks Investment ResearchZacks Investment Research upgraded shares of Minerva Neurosciences (NASDAQ:NERV) from a hold rating to a buy rating in a research report released on Wednesday morning, Zacks.com reports. They currently have $1.25 target price on the biopharmaceutical company’s stock. According to Zacks, “Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development […] |
Minerva Neurosciences (NASDAQ:NERV) Downgraded by Zacks Investment Research to HoldZacks Investment Research downgraded shares of Minerva Neurosciences (NASDAQ:NERV) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning, Zacks.com reports. According to Zacks, Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to [] |
Minerva Neurosciences (NERV) Reports Q3 Loss, Misses Revenue EstimatesMinerva Neurosciences (NERV) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock? |
Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business UpdatesCompany to Host Conference Call Today at 8:30 a.m. ET WALTHAM, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended September 30, 2021. Roluperidone Update On November 3, 2021, the Company announced that the U. S. Food and Drug Administration (FDA) denied |